Based on extensive evidence of SGLT2 inhibitors in patients with CKD, KDIGO updated its clinical practice guideline in 2022 to recommend SGLT2 inhibitors as preferred therapeutic agents for managing T2DM combined with CKD (2). Here, SLC5A2 is linked to chronic kidney disease.